UNION therapeutics A/S – Expanded Access Policy

UNION therapeutics A/S, a privately held, multi-asset, clinical stage, pharmaceutical company focused on immunology and infectious diseases is dedicated to developing new therapies, which have the potential to significantly improve the life of people living with debilitating disease.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to orismilast tablets, an investigational product which is in clinical development (Phase 2) for the treatment of moderate to severe atopic dermatitis (AD), and moderate to severe hidradenitis suppurativa (HS) in patients ages 18 years and older.

At this point of clinical development, UNION has not established an Expanded Access Program that allows patients access to orismilast outside of clinical trials. Participation in clinical trials will ensure dedicated monitoring of the efficacy and safety of the drug, which is currently the most appropriate and responsible setting of patient treatment.

Information about UNION’s clinical trials, including eligibility and locations, will be made available at clinicaltrials.gov as soon as a trial has been approved by the FDA.

UNION recognizes the importance of Expanded Access Programs and may update this policy based on data from the ongoing clinical development program.

If you are a patient or caregiver with questions about access to orismilast clinical trials, the licensed physician overseeing your care should contact UNION at info@uniontherapeutics.com. UNION will acknowledge the receipt of specific inquiries within five (5) business days.

UNION therapeutics A/S
Tuborg Havnevej 18A
2900 Hellerup
Denmark
www.uniontherapeutics.com